Vol 27, No 1 (2022)
Letter to the Editor
Published online: 2021-11-17
Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”
Rep Pract Oncol Radiother 2022;27(1):180-181.
Abstract
NA
References
- Ho AY, Wright JL, Blitzblau RC, et al. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020; 108(1): 227–241.
- Soares RF, Garcia AR, Monteiro AR, et al. Prognostic factors for early relapse in non-metastatic triple negative breast cancer — real world data. Rep Pract Oncol Radiother. 2021; 26(4): 563–572.
- Roth SL, Audretsch W, Bojar H, et al. Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol. 2010; 186(6): 299–306.
- Bondiau PY, Courdi A, Bahadoran P, et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2013; 85(5): 1193–1199.